ESR1 and breast carcinoma: The increased PPARγ-dependent and decreased NFκB-dependent and ERα-dependent gene transcription resulting from AKR1C3 inhibition is predicted to inhibit breast cancer cell proliferation, making it a potential target for breast cancer treatment.